Department of Intensive Care Medicine, Academic Medical Centre, Amsterdam, Netherlands.
Lancet. 2013 Sep 14;382(9896):984-94. doi: 10.1016/S0140-6736(12)62197-7. Epub 2013 May 1.
Three decades ago, transfusion-related acute lung injury (TRALI) was considered a rare complication of transfusion medicine. Nowadays, the US Food and Drug Administration acknowledge the syndrome as the leading cause of transfusion-related mortality. Understanding of the pathogenesis of TRALI has resulted in the design of preventive strategies from a blood-bank perspective. A major breakthrough in efforts to reduce the incidence of TRALI has been to exclude female donors of products with high plasma volume, resulting in a decrease of roughly two-thirds in incidence. However, this strategy has not completely eradicated the complication. In the past few years, research has identified patient-related risk factors for the onset of TRALI, which have empowered physicians to take an individualised approach to patients who need transfusion.
三十年前，输血相关性急性肺损伤（TRALI）被认为是输血医学中罕见的并发症。如今，美国食品和药物管理局将该综合征视为输血相关死亡的主要原因。对 TRALI 发病机制的了解促使从血库角度设计了预防策略。减少 TRALI 发生率的一项重大突破是排除具有高血浆容量的女性供体产品，从而使发病率降低了大约三分之二。然而，该策略并未完全消除该并发症。在过去的几年中，研究已经确定了与患者相关的 TRALI 发病风险因素，这使医生能够对需要输血的患者采取个体化的方法。
